Lux Capital is a venture capital firm established in 2000 and headquartered in New York, New York. The firm specializes in investments in early-stage and growth companies, focusing on sectors such as biochemistry, material science, electronics, infrastructure, and aerospace. With over $5 billion in assets under management, Lux Capital takes an active role in supporting entrepreneurs, aiming to build successful businesses in high-growth industries. The investment team has a track record of founding more than 20 companies, employing strategies that enhance connectivity, insight, and competitive leadership for its portfolio companies. As a Registered Investment Adviser, Lux Capital is committed to fostering innovation at the intersection of technology and the sciences.
Mendaera is a medtech startup that specializes in developing advanced healthcare technologies, with a focus on robotics and diagnostic tools. The company aims to enhance clinical judgment and technical expertise to make high-quality care accessible to all patients across various care facilities. Mendaera's innovative platform, currently in development, combines real-time imaging, robotics, and artificial intelligence to assist physicians in both image acquisition and interpretation. This integration facilitates precise and consistent point-of-care interventions, streamlining the patient journey, accelerating recovery, and reducing overall care costs. By empowering healthcare professionals with these advanced technologies, Mendaera seeks to improve the efficacy and accessibility of medical procedures.
Inductive Bio
Seed Round in 2023
Inductive Bio specializes in providing a machine learning platform that enhances the compound optimization process for drug development. The company focuses on addressing ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges by building comprehensive datasets and machine learning models. This enables scientists to efficiently identify and refine small molecule compounds, transforming initial candidates into viable leads more rapidly and with improved properties. By streamlining the optimization process, Inductive Bio supports the development of new therapeutics, ultimately contributing to advancements in the pharmaceutical industry.
Cromatic
Seed Round in 2023
Cromatic develops software aimed at simplifying the outsourcing of research and development for life sciences companies. By providing a platform that facilitates the identification and management of scientific outsourcing partners, Cromatic allows health-tech companies to connect with contract research organizations more efficiently. This innovation enables scientists to launch and scale their ventures without the need for a physical laboratory, allowing them to concentrate on their research and development efforts. Ultimately, Cromatic enhances the efficiency of R&D processes, empowering scientist entrepreneurs to focus on advancing scientific discovery.
Mendaera
Series A in 2023
Mendaera is a medtech startup that specializes in developing advanced healthcare technologies, with a focus on robotics and diagnostic tools. The company aims to enhance clinical judgment and technical expertise to make high-quality care accessible to all patients across various care facilities. Mendaera's innovative platform, currently in development, combines real-time imaging, robotics, and artificial intelligence to assist physicians in both image acquisition and interpretation. This integration facilitates precise and consistent point-of-care interventions, streamlining the patient journey, accelerating recovery, and reducing overall care costs. By empowering healthcare professionals with these advanced technologies, Mendaera seeks to improve the efficacy and accessibility of medical procedures.
Paradigm
Series A in 2023
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.
Osmo
Venture Round in 2023
Osmo gives computers a sense of smell that improves the health and well-being of human life. Osmo brings together frontier AI and olfactory science to tackle a historic challenge. While they are initially focused on the intricate world of fragrance, their ultimate objective is to enhance the health and well-being of human life through the sense of smell.
WellTheory
Seed Round in 2022
WellTheory is a virtual care platform providing autoimmune and inflammatory conditions care services.
H1.co
Series C in 2021
H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.
Pager
Series C in 2021
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
AllStripes
Series B in 2021
AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.
Carbon Health
Series D in 2021
Carbon Health is a technology-driven healthcare company founded in 2015 and headquartered in San Francisco, California. It provides a comprehensive primary care experience through a mobile application that allows users to manage their treatment plans, prescriptions, and lab reports in one place. The company emphasizes convenience and accessibility, offering omnichannel care through various platforms, including clinics, pop-up sites, and virtual consultations. Additionally, Carbon Health has developed a coronavirus assessment tool and has implemented COVID-19 testing services in California, further expanding its commitment to accessible healthcare.
H1.co
Series B in 2020
H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.
EverlyWell
Series D in 2020
EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.
Thrive Earlier Detection
Series B in 2020
Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.
AllStripes
Series A in 2020
AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.
Pager
Series B in 2020
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Vesta Healthcare
Series A in 2020
Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.
CTRL-Labs
Venture Round in 2019
CTRL-Labs Corporation, founded in 2015 and based in New York City, specializes in developing non-invasive neural interface technology aimed at enhancing the interaction between humans and machines. The company's flagship product, the CTRL-kit, is a wireless wristband equipped with sensors that captures neural signals, allowing users to control digital devices through simple electronic pulses. This innovative platform is designed to support various applications in virtual reality, augmented reality, robotics, productivity, and clinical research. By providing developers with a software development kit (SDK) and application programming interface (API), CTRL-Labs enables the integration of neural control into their applications. The company's long-term vision focuses on fostering mass consumer adoption of neural interfaces, establishing a new standard for human-machine collaboration that transforms how users engage with technology.
Visla Labs
Seed Round in 2018
Visla Labs Inc. is a San Francisco-based startup focused on developing an artificial intelligence platform tailored for the radiology and healthcare sectors. Incorporated in 2018, the company is dedicated to advancing healthcare technology, aiming to create innovative solutions that enhance diagnostic processes and patient care. With venture capital backing, Visla Labs is positioned for significant growth as it approaches a critical milestone in its development.
AllStripes
Seed Round in 2018
AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.
Vium
Series B in 2018
Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.
CTRL-Labs
Series B in 2018
CTRL-Labs Corporation, founded in 2015 and based in New York City, specializes in developing non-invasive neural interface technology aimed at enhancing the interaction between humans and machines. The company's flagship product, the CTRL-kit, is a wireless wristband equipped with sensors that captures neural signals, allowing users to control digital devices through simple electronic pulses. This innovative platform is designed to support various applications in virtual reality, augmented reality, robotics, productivity, and clinical research. By providing developers with a software development kit (SDK) and application programming interface (API), CTRL-Labs enables the integration of neural control into their applications. The company's long-term vision focuses on fostering mass consumer adoption of neural interfaces, establishing a new standard for human-machine collaboration that transforms how users engage with technology.
Kyruus
Corporate Round in 2018
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.
Pager
Series A in 2018
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Physera
Seed Round in 2017
Physera, Inc. is a company focused on delivering digital musculoskeletal care by connecting patients with physical therapists through a mobile application. Founded in 2015 and based in Palo Alto, California, the platform provides patients suffering from musculoskeletal injuries with access to tailored workout plans, along with features such as in-app animations and voice prompts designed to facilitate exercise therapy and alleviate pain. The application collects data to help assess the effectiveness of these routines, enabling physical therapists to create targeted recovery and maintenance plans that can be coordinated remotely. Physera serves a diverse clientele, including patients with muscular pain, self-insured employers, and large health plans. As of May 2020, Physera operates as a subsidiary of Omada Health, Inc.
3Scan
Series B in 2016
3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.
Kyruus
Series C in 2015
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.
Pager
Series A in 2015
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Pager
Venture Round in 2015
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Sols
Series B in 2015
SOLS is a software platform and mobile application that enables users to design and purchase customized orthotics for their feet. To date, the company has launched two products: SOLSRx, medical-grade 3D printed orthotics, and ExoSOLS, direct to consumer custom insoles. SOLS is now leveraging its patented footwear customization software to attack the footwear industry's biggest problem, shoe size-related returns. Founded in 2013, SOLS uses state of the art computer vision and machine learning to improve the fit and function of footwear. The company is backed by blue-chip investors like Founders Fund, Lux Capital, and Tenaya Capital and located in New York City.
3Scan
Series A in 2014
3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.
Vium
Series A in 2014
Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.
Pager
Venture Round in 2014
Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.
Sols
Series A in 2014
SOLS is a software platform and mobile application that enables users to design and purchase customized orthotics for their feet. To date, the company has launched two products: SOLSRx, medical-grade 3D printed orthotics, and ExoSOLS, direct to consumer custom insoles. SOLS is now leveraging its patented footwear customization software to attack the footwear industry's biggest problem, shoe size-related returns. Founded in 2013, SOLS uses state of the art computer vision and machine learning to improve the fit and function of footwear. The company is backed by blue-chip investors like Founders Fund, Lux Capital, and Tenaya Capital and located in New York City.
Sols
Seed Round in 2013
SOLS is a software platform and mobile application that enables users to design and purchase customized orthotics for their feet. To date, the company has launched two products: SOLSRx, medical-grade 3D printed orthotics, and ExoSOLS, direct to consumer custom insoles. SOLS is now leveraging its patented footwear customization software to attack the footwear industry's biggest problem, shoe size-related returns. Founded in 2013, SOLS uses state of the art computer vision and machine learning to improve the fit and function of footwear. The company is backed by blue-chip investors like Founders Fund, Lux Capital, and Tenaya Capital and located in New York City.
Visterra
Series A in 2013
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Kyruus
Series B in 2013
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.
Visterra
Series A in 2012
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Visterra
Debt Financing in 2010
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Visterra
Seed Round in 2009
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.